These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21208500)

  • 1. Evidence-based pharmacotherapy of schizophrenia.
    Leucht S; Heres S; Kissling W; Davis JM
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):269-84. PubMed ID: 21208500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of schizophrenia.
    Leucht S; Heres S; Kissling W; Davis JM
    Fortschr Neurol Psychiatr; 2013 May; 81(5):e1-13. PubMed ID: 23702802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of the efficacy of second-generation antipsychotics.
    Davis JM; Chen N; Glick ID
    Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.
    Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU
    Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment.
    Tandon R; Fleischhacker WW
    Schizophr Res; 2005 Nov; 79(2-3):145-55. PubMed ID: 16139989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions.
    Mantovani C; Labate CM; Sponholz A; de Azevedo Marques JM; Guapo VG; de Simone Brito dos Santos ME; Pazin-Filho A; Del-Ben CM
    J Clin Psychopharmacol; 2013 Jun; 33(3):306-12. PubMed ID: 23609398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic treatment of schizophrenia: an update.
    Bruijnzeel D; Suryadevara U; Tandon R
    Asian J Psychiatr; 2014 Oct; 11():3-7. PubMed ID: 25216917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should patients with schizophrenia receive antidepressants?
    Terevnikov V; Stenberg JH; Joffe G
    Duodecim; 2017; 133(5):465-71. PubMed ID: 29205993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.